A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2

Tom Wilkinson, Anthony De Soyza, Miles Carroll, James D. Chalmers, Michael G. Crooks, Gareth Griffiths, Manu Shankar-Hari, Ling-Pei Ho, Alex Horsley, Chris Kell, Beatriz Lara, Biswa Mishra, Rachel Moate, Clive Page, Hitesh Pandya, Jason Raw, Fred Reid, Dinesh Saralaya, Ian C. Scott, Salman Siddiqui, Andy Ustianowski, Natalie van Zuydam, Ashley Woodcock, Dave Singh

Open source

DOI: 10.1183/23120541.00249-2023
Published: 2023-08-09
Container: ERJ Open Research
Publisher: European Respiratory Society (ERS)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1183/23120541.00249-2023,
  title = {A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2},
  author = {Tom Wilkinson and Anthony De Soyza and Miles Carroll and James D. Chalmers and Michael G. Crooks and Gareth Griffiths and Manu Shankar-Hari and Ling-Pei Ho and Alex Horsley and Chris Kell and Beatriz Lara and Biswa Mishra and Rachel Moate and Clive Page and Hitesh Pandya and Jason Raw and Fred Reid and Dinesh Saralaya and Ian C. Scott and Salman Siddiqui and Andy Ustianowski and Natalie van Zuydam and Ashley Woodcock and Dave Singh},
  year = {2023},
  journal = {ERJ Open Research},
  doi = {10.1183/23120541.00249-2023},
  url = {https://doi.org/10.1183/23120541.00249-2023}
}

RIS

TY  - JOUR
TI  - A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
AU  - Tom Wilkinson
AU  - Anthony De Soyza
AU  - Miles Carroll
AU  - James D. Chalmers
AU  - Michael G. Crooks
AU  - Gareth Griffiths
AU  - Manu Shankar-Hari
AU  - Ling-Pei Ho
AU  - Alex Horsley
AU  - Chris Kell
AU  - Beatriz Lara
AU  - Biswa Mishra
AU  - Rachel Moate
AU  - Clive Page
AU  - Hitesh Pandya
AU  - Jason Raw
AU  - Fred Reid
AU  - Dinesh Saralaya
AU  - Ian C. Scott
AU  - Salman Siddiqui
AU  - Andy Ustianowski
AU  - Natalie van Zuydam
AU  - Ashley Woodcock
AU  - Dave Singh
PY  - 2023
JO  - ERJ Open Research
DO  - 10.1183/23120541.00249-2023
UR  - https://doi.org/10.1183/23120541.00249-2023
ER  -

APA

Wilkinson, T., Soyza, A. D., Carroll, M., Chalmers, J. D., Crooks, M. G., Griffiths, G., Shankar-Hari, M., Ho, L., Horsley, A., Kell, C., Lara, B., Mishra, B., Moate, R., Page, C., Pandya, H., Raw, J., Reid, F., Saralaya, D., Scott, I. C., Siddiqui, S., Ustianowski, A., Zuydam, N. V., Woodcock, A., & Singh, D. (2023). A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2. ERJ Open Research. https://doi.org/10.1183/23120541.00249-2023

Source records

crossref · retrieved 2026-09-25T12:37:10.338Z